

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Last Event Reported) July 19, 2007.  
-----

**HEALTHCARE ACQUISITION CORP.**

-----  
(Exact Name of Registrant as Specified in Charter)

**Delaware**

-----  
(State or Other Jurisdiction  
of Incorporation)

**001-32587**

-----  
(Commission  
File Number)

**20-2726770**

-----  
(IRS Employer  
Identification No.)

**2116 Financial Center 666 Walnut Street  
Des Moines, Iowa**

-----  
(Address of Principal Executive Offices)

**50309**

-----  
(Zip Code)

Registrant's telephone number, including area code: **(515) 244-5746**  
-----

**Not Applicable**

-----  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events**

On July 19, 2007, Healthcare Acquisition Corp. (the "Company") issued a press release with respect to its special meeting of stockholders to be held on July 27, 2007 to approve the previously announced acquisition of PharmAthene, Inc. A copy of the Company's press release is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release dated July 19, 2007 issued by Healthcare Acquisition Corp.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 23, 2007

**HEALTHCARE ACQUISITION CORP.**

By: /s/ Matthew P. Kinley

\_\_\_\_\_  
Matthew P. Kinley

President

**Contact:**

Matthew Kinley  
Healthcare Acquisition Corp.  
Phone: 515-244-5746  
kinley@pappajohn.com

**HEALTHCARE ACQUISITION CORP. ANNOUNCES SPECIAL MEETING OF STOCKHOLDERS TO VOTE ON PROPOSED MERGER WITH PHARMATHENE AND ANNOUNCES MAILING OF PROXIES TO STOCKHOLDERS OF RECORD**

**DES MOINES, IOWA July 19, 2007** - Healthcare Acquisition Corp. (AMEX: HAQ), a publicly-traded special purpose acquisition company, announced that it has scheduled a special meeting of its stockholders to vote on, among other things, the proposed merger transaction with PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures against biological and chemical threats. The special meeting will be held on July 27, 2007 at 10:00 a.m. Eastern Time at the offices of McCarter & English, LLP, 245 Park Avenue, 27<sup>th</sup> Floor, New York, NY. Other proposals related to the proposed merger transaction will also be voted on. The record date for stockholders entitled to vote at the special meeting was fixed as the close of business on June 15, 2007.

Definitive proxy materials relating to the special meeting were filed with the U.S. Securities and Exchange Commission on July 13, 2007 and such materials were mailed to HAQ stockholders of record on or about July 16, 2007. HAQ's stockholders are urged to read the proxy statement and other relevant materials if and as they become available as they will contain important information about the proposed merger and the related proposals.

The Board of Directors of HAQ unanimously recommends that stockholders vote "for" each of the proposals related to the proposed merger transaction. Additional information about the proposed merger and each of the other proposals can be found in the definitive proxy statement.

HAQ stockholders with questions about the proposed merger or any of the other proposals or who need assistance in voting their shares may call the Company's proxy solicitor, Morrow & Co., Inc., toll-free at (800) 607-0088.

**Additional Information**

HAQ AND ITS DIRECTORS AND EXECUTIVE OFFICERS AS WELL AS PHARMATHENE AND ITS DIRECTORS AND EXECUTIVE OFFICERS MAY BE DEEMED TO BE PARTICIPANTS IN THE SOLICITATION OF PROXIES FOR THE SPECIAL MEETING OF HAQ'S STOCKHOLDERS TO BE HELD TO APPROVE THE PROPOSED MERGER. SECURITYHOLDERS AND OTHER INTERESTED PERSONS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED MERGER FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 13, 2007, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. STOCKHOLDERS WILL ALSO BE ABLE TO OBTAIN A COPY OF THE DEFINITIVE PROXY STATEMENT, WITHOUT CHARGE, BY DIRECTING A REQUEST TO HAQ AT: **2116 FINANCIAL CENTER, 666 WALNUT STREET, DES MOINES, IOWA 50309**. THE DEFINITIVE PROXY STATEMENT AND THE FINAL PROSPECTUS AND OTHER SEC FILINGS OF HAQ CAN ALSO BE OBTAINED, WITHOUT CHARGE, AT THE SECURITIES AND EXCHANGE COMMISSION'S INTERNET SITE (<http://www.sec.gov>).

---

HAQ AND PHARMATHENE CLAIM THE PROTECTION OF THE SAFE HARBOR FOR “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF HAQ AND PHARMATHENE REGARDING, AMONG OTHER THINGS, THE BUSINESS OF PHARMATHENE AND THE MERGER, ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES INCLUDE RISKS ASSOCIATED WITH THE RELIABILITY OF THE RESULTS OF THE INITIAL WORK CONDUCTED ON VALORTIM™ RELATING TO ANIMAL EFFICACY, HUMAN SAFETY AND LIKELIHOOD OF SUCCESSFUL DEVELOPMENT OF AN EFFICIENT AND SCALABLE MANUFACTURING PROCESS, UNEXPECTED FUNDING DELAYS BY NIAID, UNFORESEEN SAFETY ISSUES RESULTING FROM THE HANDLING OF BACILLUS ANTHRACIS, UNFORESEEN SAFETY ISSUES RESULTING FROM THE ADMINISTRATION OF VALORTIM™ (MDX-1303) IN HUMAN SUBJECTS, UNCERTAINTIES RELATED TO PRODUCT MANUFACTURING. THERE CAN BE NO ASSURANCE THAT SUCH DEVELOPMENT EFFORTS WILL SUCCEED OR THAT OTHER DEVELOPED PRODUCTS WILL RECEIVE REQUIRED REGULATORY CLEARANCE OR THAT, EVEN IF SUCH REGULATORY CLEARANCE WERE RECEIVED, SUCH PRODUCTS WOULD ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.

#### **About Healthcare Acquisition Corp.**

Des Moines-based Healthcare Acquisition Corp. was jointly formed by healthcare investing pioneers, John Pappajohn and Derace L. Schaffer, M.D. Healthcare Acquisition Corp. is a special purpose acquisition company focused on the healthcare industry. The Company raised \$75.2 million through an IPO in July, 2005. As of September 30, 2006, the Company held approximately \$70 million in trust. The Company’s shares trade on the American Stock Exchange, under the symbol HAQ and its warrants trade on the American Stock Exchange under the symbol HAQW.

#### **About PharmAthene, Inc.**

PharmAthene, a privately-held biodefense company, was formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene’s lead programs include Valortim™ (being co-developed with Medarex, Inc. [NASDAQ: MEDX]) and Protexia®. For more information on PharmAthene, please visit its website at [www.PharmAthene.com](http://www.PharmAthene.com).

###